CAS: 2009-84-9; 2-((6-Chlorohexyl)Oxy)Tetrahydro-2H-Pyran

相似化合物

1852573-27-3 2009-83-8 42330-88-1

上下游产品

CAS号110-87-2 3,4-二氢-2H-吡喃 | CAS号2009-83-8 6-氯-1-己醇 | CAS号53963-10-3 2-(6-溴己氧基)四氢吡喃 | CAS号4286-55-9 6-溴正己醇 | CAS号82407-42-9 1-hydroxy-7-(3-... | CAS号111-27-3 正己醇 | CAS号629-30-1 1,7-庚二醇 | CAS号13857-04-0 acetic acid,dec... | CAS号16695-32-2 2-(7-Dodecynylo... | CAS号20056-92-2 顺-7-十二烯-1-醇 | CAS号37011-95-3 (E)-7-Tetradece... | CAS号37011-94-2 7-TETRADECYN-1-OL

3,4-二氢-2H-吡喃置于对甲苯磺酸体系中,用 二氯甲烷 用作溶剂,化学反应 16.0H,以74%的收率获得2-(6-氯己氧基)四氢-2H-吡喃
参考文献:Wo2006/50609
标题:Wo2006/50609

专利信息

专利号:US-3943157-A
优先权日:1971-07-26
标题 :Synthesis of codling moth attractant
发明人：HENRICK CLIVE A; SIDDALL JOHN B
权利人:ZOECON CORP
摘要:Sterospecific synthesis of an attractant for the codling moth by reacting sorbic aldehyde with an organo-metallic reagent to yield a 1-ether of trans-8-trans-10-dodecadiene-1,7-diol which is reduced via a 7-sulfonic acid ester to yield an ether of trans-8-trans-10-dodecadiene-1-ol and hydrolyzed to trans-8-trans-10-dodecadien-1-ol. ##SPC1##

专利号:WO-2008084057-A1
优先权日:2007-01-10
标题:Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
发明人：LANGE JOSEPHUS H M; KRUSE CORNELIS G
权利人:SOLVAY PHARM BV; LANGE JOSEPHUS H M; KRUSE CORNELIS G
摘要:This invention relates to compounds with a combination of cannabinoid-CB1antagonism and serotonin reuptake inhibition to pharmaceutical compositions containing these compounds, to methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders. In particular the invention relates to compoundsof the general formula (I): wherein the symbols have the meanings given in the specification.

专利号:US-2013190399-A1
优先权日:2009-10-31
标 题:Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA)
发明人：RAMAN KRISHNA; TARWADE VINOD
权利人:RAMAN KRISHNA; TARWADE VINOD; MARTEK BIOSCIENCES CORP
摘要:The invention provides methods of synthesizing omega-3 and omega-6 very long chain polyunsaturated fatty acids (VLC-PUFAs, C28-C42:4, 5 and 6), analogs and derivatives thereof, pharmaceutical compositions containing these isolated VLC-PUFA compounds and therapeutic uses therefor.

专利号:US-8138174-B2
优先权日:2007-01-10
标 题:Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
发明人：LANGE JOSEPHUS H M; KRUSE CORNELIS G
权利人:LANGE JOSEPHUS H M; KRUSE CORNELIS G; SOLVAY PHARM BV
摘要:Compounds with a combination of cannabinoid CB 1 antagonism and serotonin reuptake inhibition, pharmaceutical compositions containing these compounds, methods for preparing these compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing these compositions are disclosed. Uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders are disclosed. n In at least one embodiment, the invention relates to compounds of the general formula (1): n nwherein the substitutents have the definitions given in the specification.

专利号:WO-2011053892-A1
优先权日:2009-10-31
标 题:Synthesis and use of omega-3 and omega-6 very long chain polyunsaturated fatty acids (vlc-pufa)
发明人：RAMAN KRISHNA; TARWADE VINOD; SALEM NORMAN JR
权利人:MARTEK BIOSCIENCES CORP; RAMAN KRISHNA; TARWADE VINOD; SALEM NORMAN JR
摘要:The invention provides methods of synthesizing omega-3 and omega-6 very long chain polyunsaturated fatty acids (VLC- PUFAs, C28-C42:4,5 and 6), analogs and derivatives thereof, pharmaceutical compositions containing these isolated VLC-PUFA compounds and therapeutic uses therefor.